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Abstract:
Alzheimer’s disease (AD) is a neurodegenerative disorder whose exact cause(s) are still
unknown. Εpsilon 4, an allele of apolipoprotein E (ApoE4), is currently the most important risk
factor for Alzheimer’s disease. Individuals that inherit two copies of the ApoE ε4 allele have an
approximately ten to thirty times increased risk of developing AD in comparison to persons not
carrying this allele. This association may relate to ApoE4’s susceptibility to proteolysis and
neurotoxicity. Amyloid precursor protein (APP) is involved with neurite extension and neurite
retraction, and has been shown to function as a molecular switch with two separate cleavage
patterns. Cleavage at the β-, γ-, and caspase sites results in the production of four neurotoxic,
pro-apoptotic, pro-AD peptides: sAPPβ, Aβ, Jcasp, and C31. In contrast, anti-AD cleavage at the
α-site produces two neuroprotective peptides: sAPPα and αCTF. Recent data have shown
significantly lower sAPPα levels in cerebrospinal fluid of AD patients who possess one or more
ε4 allele. Recent research studies have focused attention on Sirtuins. SirT1 plays a role in
synaptic plasticity, learning and memory. Additionally, it has been demonstrated to reduce Aβ
accumulation and elevate α-secretase activity. ApoE4 has been suggested to decrease SirT1.
SirT1 suppresses AD in cells, primary neurons, and mouse models, by activating transcription of
ADAM10, thus increasing the levels of the neuroprotective sAPPα, which is the pro-ligand
peptide. In addition, overexpression of SirT1 causally promotes α-secretase activity and
attentuates Aβ peptides generation in primary neuron cultures. Using various methods, SirT1
demonstrates having an effect on ApoE4 and may have an interaction either directly or
indirectly.
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Abbreviations:

Alzheimer’s Disease: AD

Beta Amyloid: Aβ

Sirtuin1: SirT1

Apolipoprotein E4: ApoE4

Amyloid Precursor Protein: APP

Immunocytochemistry: ICC

Co-immunoprecipitation: Co-Ip
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Overview:
Two main hallmarks of Alzheimer’s disease (AD) are the depositon of fibrillar amyloid β
peptides (Aβ) in senile plaques of the brain and hyperphosphorylation of tau proteins, which lead
to loss of synapses and dendritic spines (Wang et al.,2013 and Hashimoto et al., 2012). The
amyloid precursor protein (APP) has been shown to function as a molecular switch: cleavage at
the β, γ, and caspase sites results in the production of four pro-AD-peptides—sAPPβ (from
which N-APP is derived), Aβ, Jcasp, and C31—that mediate neurite retraction, synaptic
reorganization, and ultimately programmed cell death (Bredesen et al., 2010; Bredesen et al.,
2006; Butterfield et al., 2010). In contrast, cleavage at the α site produces the trophic peptide
sAPPα and the inhibitor of APP γ-site cleavage, αCTF (Bredesen, 2009). The decision between
these two proteolytic pathways is governed at least in part by ligand binding: interaction with the
axon guidance and trophic factor netrin-1 increases α-site cleavage, whereas interaction with the
anti-trophin Aβ inhibits α-site cleavage and increases net production of the four neuriteretractive peptides (Bredesen, 2009) [Fig 1]
The apolipoprotein E4 (ApoE4) (chromosomal locus 19q13) is the single most important
genetic risk factor associated with AD. This allele confers increased risk for sporadic as well as
familial AD (Mahley et al., 2006; Roses, 1996). Individuals with two copies of the ApoE ε4
allele have an approximately eightfold increased risk of AD and have a significantly lower age of
onset compared to AD patients not carrying this allele (Mahley et al., 2006; Roses, 1996). While
the exact mechanism of ApoE4 toxicity remains unclear, recent data indicate that the greater risk
of AD associated with the ApoE4 isoform might relate to ApoE’s susceptibility to proteolysis
and neurotoxicity (Mahley et al., 2006). According to a recent study, the level of CSF sAPPα is
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significantly lower in AD patients possessing one or two ApoE4 alleles than in those not
possessing the ApoE4 allele (Olsson et al., 2003). Therefore, it was of interest to determine

!

Figure 1: APP acts as a molecular switch: Alternative cleavage of APP at the β, γ and caspase
sites leading to four peptides namely; Aβ, sAPPβ, Jcasp and C31 that mediate synaptic loss,
neurite retraction, and ultimately programmed cell death; or cleavage at the α-site leading to two
peptides namely sAPPα and αCTF that mediate neurite extension, synaptic maintenance and
inhibit programmed cell death. Among the factors that mediate the decision between these two
pathways are included trophic effects such as netrin-1 and anti-trophic effects such as Aβ peptide
(Bredesen, 2009).
whether ApoE isoforms impact this trophic-anti-trophic peptide balance differentially, and, if so,
by what mechanism.
Recent studies point to SirT1, which belongs to the Sirtuin family of NAD-dependent
deacetylases as being neuroprotective and SirT2 as being neurotoxic. SirT1 suppresses AD in a
mouse model for this disease by directly activating transcription of ADAM10 and increasing the
levels of the neuroprotective sAPPα(Donmez et al., 2010; Julien et al., 2009). Since one of the
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mechanisms by which ApoE4 could trigger reduction in sAPPα levels is by inhibiting the
proteolysis of APP at the α-site, it was of interest to determine the effect of ApoE isoforms on
SirT1 and SirT2 expression. By identifying if this relationship is significant by various methods,
we should gain insight into the underlying processes driving Alzheimer’s disease: Furthermore,
this may help us to develop therapeutic remedies that can increase SirT1 levels, therefore
increasing sAPPα and decreasing Aβ.
Specific Aims:
In order to further understand the mechanisms underlying Alzheimer’s disease, the
interaction between ApoE and APP must be understood more clearly, and also we must
understand the proposed relationship between ApoE and Sirtuins. If there is an interaction
between ApoE4 and Sirtuins, then this discovery may give us the necessary data to discover
whether SirT1 and SirT2 are important in AD, and, if so, how ApoE is affecting this proposed
relationship. Three specific aims I intend to accomplish in order to answer the question about
the relationship between ApoE4 and Sirtuins are:
AIM 1: Cellular localization of ApoE.
APP and ApoE have been shown to interact with each other in the cell, and identifying in which
cellular compartment(s) this occurs should give us insight into how they interact.

AIM 2: Does ApoE interact with Sirtuins?
One of the mechanisms by which ApoE affects pro-AD vs anti-AD peptide formation is by
affecting SirT1 or SirT2 levels. To understand this better, we will be looking at ApoE-SirT
interaction by immunoprecipitations and immunocytochemistry
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AIM 3: Drugs that will affect ApoE-SirT interaction and increase sAPPα.
Our data thus far indicate that APP, ApoE and SirT1/2 all may be part of a network that is
affected in AD. Thus our data provide a medium-throughput model for therapeutic candidate
screening directed at this network of molecules that needs to be considered as a critical target for
AD drug discovery.

Background:
Alzheimer’s disease (AD) is a progressive neurodegenerative disease of the central
nervous system (Capsoni et al.,2002). AD affects about 5 million Americans, and by 2050, this
is expected to increase to 13 million people.

The cost of AD in the United States is

approximately $200 billion annually. Among people who are 65 and older, 15%(1 in 7 people)
are diagnosed with AD and for those who are above age 85, 50%(1 in 2 people) are diagnosed
(Bonda et al., 2011). Neurofibrillary tangles and senile plaques are the two main hallmarks of
the disease. Although not all aspects of AD are fully understood, research in the field has come
across some risk factors and mediators but understanding of the pathogenesis remains
incomplete, and there is no truly effective treatment. The senile plaques are predominantly
composed of β-amyloid (Aβ). After the amyloid precursor protein (APP) is cleaved by β- and γsecretase, Aβ is formed. One of the causes of early onset familial AD (FAD; Capsoni…) is
mutations in APP that lead to extracellular deposition of Aβ, this is one cause of early onset
familial AD (Capsoni et al.,2002). APP has been shown to function in synaptic transmission and
plasticity as well as in cell adhesion and motility. When APP interacts with netrin-1, neurite
extension occurs, but when it interacts with Aβ, neurite retraction takes place, and ultimately cell
death (Lourenco et al.,2009). APP is produced in large quantities in neurons and is metabolized
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very rapidly. After sorting in the endoplasmic reticulum and Golgi, APP is delivered to the
axon, where it is transported by fast axonal transport to synaptic terminals. On the cell surface,
APP can be proteolyzed directly by α-secretase and then γ-secretase, a process that does not
generate Aβ, or reinternalized in clathrin-coated pits into another endosomal compartment
containing the proteases BACE1 and γ-secretase. The latter results in the production of Aβ,
which is then dumped into the extracellular space following vesicle recycling or degraded in
lysosomes. This part is very rapid, as little APP is on the surface at any point in time. BACE1 is
the neuronal β-secretase and following BACE1 cleavage and release of the sAPPβ ectodomain,
the APP C-terminal fragment is cleaved by the γ-secretase complex at one of several sites
varying from +40 to +44 to generate Aβ and the APP intracellular domain (O’Brien et al., 2011).

Figure 2: Neurofibrillary tangles and senile plaques in AD. The neurofibrillary tangles are
made up of hyperphosphorylated tau, which leads to synapse lose. The dominant material in the
senile plaques is Aβ.
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Pathology of autosomal dominant AD is very similar to sporadic AD, including neurofibrillary
tangles and microglial infiltration. There are 32 APP, 179 PSEN1 (presenilin 1 gene locus), and
14 PSEN2 gene mutations that result in early-onset, autosomal dominant, and fully penetrant
AD. In APP, mutations cluster around the γ-secretase cleavage site, although the most famous
APP mutation (APP-SWE) causes a change in amino acids adjacent to the BACE1 cleavage site.
PSEN gene mutations (which give rise to proteins called presenilins, PS1 and PS2)
predominantly alter the amino acids in their nine trans-membrane domains. The common thread
to all these mutations is that they increase production of the less soluble and more toxic Aβ42
relative to Aβ40 (O’Brien et al., 2011).
Neurofibrillary tangles, the other hallmark of AD, are made up of hyperphosphorylated
tau in the brain [Fig 2]. The phosphorylation of tau leads to synapse loss. Aβ has been linked to
tau entering into dendrites, which is associated with the loss of synapses, spines, and
microtubules (Wang et al.,2013 ). Apolipoprotein E (ApoE) is known to bind to Aβ in plaques
of the brain. The ApoE gene has three isoforms, ε2, ε3, and ε4. Inheritance of two copies of the
ApoE ε4 allele increases the risk for developing AD by 10-fold compared to the ApoE ε3/ε3
genotype (Hashimoto et al.,2012). ApoE2 has been shown to decrease the risk compared to the
other alleles. It remains unclear how ApoE affects plaque morphology, but in AD patients it has
been shown that ApoE4 increases plaque deposition compared to ApoE2 and ApoE3 in humans
(Youmans et al.,2012).
Recent research studies have focused attention on Sirtuins and their role in AD. Seven
sirtuin genes are encoded by the human genome, SirT1 is the most well known. SirT1 which
was first identified in yeast is a NAD(positive)-dependent enzyme that is a stress-response
protein and helps mammals adapt to dietary manipulations. Sirtuins function by removing acetyl
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groups from lysines while hydrolyzing NAD. SirT1 is predominantly found in the nucleus but
has been reported to shuttle between the nucleus and the cytoplasm. SirT2 has been identified in
the cytoplasm.

SirT1 plays a role in synaptic plasticity, learning, and memory (Bonda et

al.,2011). Additionally, it has been demonstrated to reduce Aβ accumulation and elevate αsecretase activity. In another study, SirT1 was shown to protect against microglia-dependent Aβ
toxicity in cells through inflammatory NF-kB signaling (Lalla and Donmez, 2013). In contrast,
SirT2 binds and deacetylates the transcription factor, FOXO3a, which leads to cell death under
oxidative stress (Albani et al., 2010). These two types of sirtuins may have a purpose in
Alzheimer’s disease based on the levels found in the brain of each one. Recently, Dr. Rammohan
Rao, and colleagues discovered that ApoE4 expression decreases SirT1 and increases SirT2
levels (Theendakara et al., 2013), which is associated with oxidative stress, inflammation, and
diabetes mellitus. These in turn are all risk factors in Alzheimer’s disease (Albani et al.,2010).
Results:
1. Cellular localization of ApoE4: A172 cells were either left untransfected (Figure 3A) or
transfected with ApoE4 using lipofectamine (Figure 3B). Both sets of cells were fixed to an 8well chamber slide and permeabilized in 0.3 % Triton. Both were stained with Alexa fluor 488
(green) and with DAPI (red/pink). The Alexa fluor 488 was administered at a 1:300 dilution.
Using a confocal microscope, the images fluorescence were viewed and imaged. As shown in
Fig 3, untransfected cells displayed some diffuse distribution of ApoE4 in the cytoplasmic
region, however after transfection, ApoE4 staining was more intense and this increased staining
was associated with the nucleus as well (Fig 3 B & C).
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A

B

C
Figure 3: Localization of ApoE4 by immunocytochemistry. ApoE4 was found to be in the
nucleus and cytoplasm in A172 cells before (A) and after transfection with ApoE4 (B). For the
detection of ApoE, cells were stained with a mouse monoclonal anti-ApoE antibody as primary
antibody and 488-conjugated donkey antimouse IgG as the secondary antibody (green).Nuclei
(pink/red) are counterstained using VectaShield Mounting Medium with DAPI. Staining was
observed at 63X objective with confocal microscope. (C). Using the Zen 2011 software, colocalization was viewed by showing yellow where ApoE4 is seen in the nucleus.
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Cellular localization of ApoE4 was also determined by subcellular fractionation studies. ApoE3
and ApoE4 were transfected into A172 cells and subcellular fractions were obtained using a
combination of specific buffers. Fractionation of the nucleus and cytoplasm was performed on
these cells followed by SDS/PAGE and western blotting. PARP was used as a control for the
nucleus to ensure that the extracts were pure.

In addition to being predominantly in the

cytoplasm both ApoE3 and E4 were also seen to be present in the nucleus [Fig 6A].
The exact pathway by which ApoE, which is normally destined for secretion, is able to
reach and enter the nucleus remains unknown. Our results showing ApoE presence in the nucleus
suggested that an active transport pathway may be involved, rather than a diffusion-based
mechanism since large proteins (>30 kDa) require an active transport pathway largely mediated
by importins (Yoneda, Y., (2000). Nucleocytoplasmic trafficking also requires the presence of
NLSs (nuclear localization sequences) that are short stretches of basic amino acids. ApoE does
contain two polybasic domains that fulfill the criterion for a potential ‘weak’ NLS (Saito, H., et
al, 2003).

2. ApoE’s interaction with Sirtuins: Recent studies have shown that SirT1 which belongs to
the Sirtuin family of NAD-dependent protein deacetylases, suppresses AD-related biochemical
events in cells, primary neurons, and mouse models by directly activating transcription of
ADAM10, thus increasing the levels of the neuroprotective sAPPα (Donmez G, et al, 2010). We
decided to investigate the role of ApoE on SirT expression. As shown in Fig 4a, ApoE4 but not
ApoE3, significantly down-regulated SirT1 gene expression without having any significant
effect on SirT2 or SirT6 expression. Furthermore, the presence of either ApoE3 or ApoE4
resulted in a significant
15	
  
	
  
	
  

reduction in SirT1 protein levels (Fig. 4b).

Fig 4. ApoE’s effects on Sirtuin expression in cells and AD postmortem tissue. Following
transfection of A172 cells with ApoE isoforms, cell pellets were collected and used for RNA
isolation and PCR or for SDS/PAGE and WB. (a) The real-time PCR cycling was performed as
described (Theendakara et al, Proc Natl Acad Sci; 110(45); 18303-8; 2013). Data (δCt values
expressed as percentage of untransfected control) are from three experiments performed in
triplicate, *P < 0.05. (b) Cell extracts were subjected to SDS/PAGE and WB to detect SirT1, T2,
and T6. Band densities are expressed as a percentage of untransfected control. (c)
Representative immunoblots probed for SirT1, T2, and T6 from homogenates of the
temporoparietal region of control subjects and AD patients. Band densities are expressed as a
percentage of normal human brains. Overexpression of SirT1 reverses ApoE4-mediated
reduction in sAPPα. Following transfection of A172 cells with ApoE4 and SirT1 (1:1 and 1:2,
respectively), sAPPα secreted into the medium (d) was assayed. (e) Cell extracts were subjected
to IP with an N-terminal anti-APP antibody followed by SDS/PAGE and WB to detect sAPPα.
In contrast, while the presence of ApoE3 resulted in a commensurate reduction in SirT2 levels,
the presence of ApoE4 triggered a ~2-fold increase in SirT2 expression. Thus the ratio of
SirT2:SirT1 was unaffected by ApoE3, but increased markedly—approximately 4.5-fold—by the
16	
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B

C
Figure 5: Effect of ApoE on cellular localization of Sirtuin. A172 cells were either left
untransfected (A) or transfected with SirT1 in the absence of ApoE4 (B) or together with ApoE4
(C) using lipofectamine. Cells were fixed to an 8-well chamber slide and permeabilized in 0.3 %
Triton. Cells were stained with Alexa fluor 488 (green) and with DAPI (red/blue). The Alexa
fluor 488 was administered at a 1:300 dilution. Using a confocal microscope, the images
fluorescence were viewed and imaged.
expression of ApoE4 (Fig. 4b). Similar to the cell culture results, the SirT2:SirT1 ratio was also
increased in human AD subjects, although in these advanced cases, this effect was solely due to a
reduction in SirT1 expression (Fig. 4c). Overexpression of SirT1 reversed the ApoE4-mediated
reduction in sAPPα secretion and restored it to normal levels (Fig. 4d).
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Additionally,

overexpression of SirT1 reversed ApoE4-mediated decrease in sAPPα protein levels (Fig. 4e).
To better understand the mechanism by which ApoE4 triggered reduction in SirT1 levels we
looked

at

ApoE-SirT

interaction

and

localization

by

immunoprecipitation

and

immunocytochemistry.

3. Effect of ApoE on cellular localization of Sirtuin: A172 cells were either left untransfected
(Figure 5A) or transfected with SirT1 in the absence of ApoE4 (Figure 5B) or together with
ApoE4 (Figure 5C) using lipofectamine. As shown in Fig 5A, untransfected cells displayed
some nuclear and diffuse cytosolic distribution of SirT1. Increased staining in both cellular
compartments was observed after transfection of SirT1 (Fig 5B). However after transfection of
ApoE4, SirT1 staining was diminished considerably in both compartments suggesting a ApoE4mediated reduction in SirT1 expression (Figure 5C).
We also confirmed the above-mentioned results with subcellular fractionation studies.
SirT1 and ApoE3 or ApoE4 were transfected into A172 cells and subcellular fractions were
obtained using a combination of specific buffers. Fractionation of the nucleus and cytoplasm was
performed on these cells followed by SDS/PAGE and western blotting. As shown in Figure 6,
SirT1 was seen only in the nucleus when ApoE3 is transfected into the cells, but in presence of
ApoE4, SirT1 was shown to be both in the cytoplasm and the nucleus. The exact mechanism is
still unclear, but the fractionation does display a clear difference between ApoE3 and ApoE4
effects on SirT1 (Figure 6A). This distinct difference may result from an interaction, direct or
indirect, between both ApoE and SirT1.
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Figure 6: Cellular localization of Sirtuin by subcellular fractionation. SirT1 and ApoE3 or
ApoE4 were transfected into A172 cells and subcellular fractions were obtained using a
combination of specific buffers. Fractionation of the nucleus and cytoplasm was performed on
these cells followed by SDS/PAGE and western blotting. PARP was used as a control for the
nucleus to ensure that the extracts were pure. SirT1 is present in both the nucleus and the
cytoplasm when ApoE4 is present and is only in the nucleus when ApoE3 is present. PARP is
used as a control for the nucleus. (B) Co-immunoprecipitation of ApoE and SirT1.
Coimmunoprecipitation was carried out in A172 cells transfected with 6 µg of FLAG-SirT1
cDNA and ApoE3 or ApoE4 expression construct. 24h after transfection, cells were gently
lifted and washed once with PBS at room temperature. Immunoprecipitations were performed
with anti-Flag monoclonal antibody (to pull down Flag-tagged SirT1), and the resulting
immunoprecipitates were subjected to SDS-PAGE and Western blotting using antisera specific
for ApoE. Membranes were probed with anti-GAPDH antibody that served as a loading control.
Lane 1 represents the extract loaded before the pull down to identify SirT1 and ApoE bands.
To determine if there was any interaction between ApoE and SirT1 at the protein level, FLAGSirT1 cDNA was expressed following transfection of A172 cells. Immunoprecipitation was
performed with anti-Flag monoclonal antibody (to pull down Flag-tagged SirT1) and the
resulting immunoprecipitates were analyzed by immunoblotting using antisera specific for
ApoE. As shown in Fig 6B, there was no evidence of direct interaction between SirT1 and
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ApoE4 at the protein level, which leads us to believe that either there is an indirect interaction or
ApoE-SirT interact at a protein-DNA level.
4. Drugs that will affect ApoE-SirT interaction and increase sAPPα. Given the effect of
ApoE4 to reduce sAPPα levels and the reversal of this effect by SirT1, it would be of interest to
identify drug candidates that return the SirT1 levels to normal in the presence of ApoE4.
A

B
Figure 7: Drugs that reverse ApoE4 effects on SirT1. A172 cells were transfected with
ApoE4. Drug treatment was done at 2.5µM for 24 hours. (A) Real-time PCR was used to obtain
SirT1 levels. The real-time PCR cycling was performed as described (Theendakara et al, Proc
Natl Acad Sci; 110(45); 18303-8; 2013). Data (dCt values expressed as percentage of
untransfected control) are from more than three experiments performed in triplicate (B) Twenty
four hours after transfecting A172 cells with ApoE4, SirT1 enzyme activity was determined
with the AlphaLISA immunoassay research kit (Perkin Elmer) according to the manufacturer’s
protocol (Theendakara et al, Proc Natl Acad Sci; 110(45); 18303-8; 2013). Data (mean ± SE)
are from four experiments performed in triplicate.
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Such candidates would potentially prevent similar effects of ApoE4 in vivo.

Therefore,

candidates identified from an earlier library screen that successfully increased sAPPα levels
were evaluated for their effects on SirT1 in the presence of ApoE4. A172 cells were transfected
with ApoE4 in a 9-well plate. After 24 hours the drug candidates were administered at a 2.5µM
concentration for 24 hours, and then the cells were harvested for assay. Real-time PCR was done
to measure the content of SirT1 in each sample. All of these drug candidates showed an increase
of SirT1 mRNA (Figure 7A). These drug candidates also showed an increase in SirT1 protein
activity levels (Figure 7B).
Furthermore, we also screened our small molecule library for drugs that will reverse the
ApoE4-mediated reduction in ADAM10 mRNA and sAPPα levels. A172 cells were transfected
with ApoE4 in a 9-well plate. The cells were treated with different drugs at 2.5µM concentration
for 24 hours. Using a real-time PCR the levels of ADAM-10 (which function as an α-secretase
and thus produces sAPPα) were determined.

The level of ADAM10 mRNA, which was

decreased in the presence of ApoE4, was reversed by a subset of the drugs that were chosen
(Figure 8A).
Similarily, there was a modest increase in sAPPα levels in the cells treated with the drugs
compared to the cells that were transfected with ApoE4 (Figure 8B).
Discussion: Based on the work done so far by others in the lab and by me, our data reveal
differential effects of ApoE4 vs. ApoE3 on APP interaction, signaling, and processing, and are
compatible with the notion that the Alzheimer’s phenotype represents an imbalance between the
trophic and anti-trophic signaling of APP, reflected by the ratio of the four APP-derived neuriteretractive peptides to the two APP-derived trophic peptides.
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Figure 8: Drugs that reverse ApoE4 effects on sAPPα. A172 cells were transfected with
ApoE4. Drug treatment was done at 2.5µM for 24 hours. (A)	
  Real-time PCR was used to obtain
ADAM10 levels. The real-time PCR cycling was performed as described (Theendakara et al,
Proc Natl Acad Sci; 110(45); 18303-8; 2013). Data (ADAM10-δCt values expressed as
percentage of untransfected control) are from more than three experiments performed in
triplicate. (B) A172 cells were transfected with ApoE4. Twenty four hours after transfection,
sAPPα secreted into the medium was determined with the AlphaLISA immunoassay research kit
(Perkin Elmer) according to the manufacturer’s protocol with some modifications (Theendakara
et al, Proc Natl Acad Sci; 110(45); 18303-8; 2013).
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Our results indicate that ApoE4 interacts with high affinity with APP, shifting the processing
balance in the anti-trophic direction, decreasing sAPPα secretion, and reducing sAPPα/Aβ and
sAPPα/sAPPβ ratios in comparison to ApoE3.

In addition to these effects on APP processing and signaling, ApoE4 expression was also
associated with a marked reduction in the ratio of SirT1 to SirT2, both in cultured neural cells
and in the brains of patients with AD.

Our data may thus explain why the ApoE4 allele is the major risk factor or susceptibility gene
associated with AD, and therefore represents an excellent target for AD drug discovery.

Our studies link for the first time the major risk factor for Alzheimer’s disease-ApoE4 with
major longevity determinants, the Sirtuins; and identify the first candidate therapeutics that target
this new link.

Our results are compatible with the notion that ApoE4-mediated signaling affects an endogenous
program that mediates synaptic plasticity balance and may explain why ApoE4 allele is the
major susceptibility gene associated with AD and should therefore be considered a critical target
for AD drug discovery.

Thus far, our data indicate that ApoE4, p-APP, p-Tau, and SirT1 all may be part of a signaling
network that is affected in AD, providing a medium-throughput model for therapeutic candidate
screening in AD drug discovery.
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Research Design and Methods:
Immunocytochemistry (ICC):
ICC is beneficial to answer the question of where ApoE localizes within the cell because
this technique uses antibodies that target specific protein antigens. For cells, A172 cells, which
are human glioblastoma cells, were used. These cells were fixed and then probed with an
antibody in order to look at different cellular compartments that can be examined using a
confocal microscope. These results allowed visualization of the cell where ApoE localizes and
also if it reacts with APP in the nucleus or the cytoplasm. One anticipated problem that could
occur with this procedure is keeping the cells alive, because transfecting the cells on a slide can
be difficult to do (in comparison to the usual transfection in cell culture plates) without killing
them. Trying different amounts of transfection quantities allowed the most appropriate amounts
to be used in order to provide optimum results. Immunocytochemistry was also used to look at
the interactions between ApoE4 and Sirtuins in the cell lines: A172 and SH-SY5Y. The same
method noted above was used, but instead looked at whether ApoE and SirT1 interact and where
in the cell this interaction occurs if it in fact does.
Cell Transfection:
A172 cells express APP endogenously, so they were transfected with the ApoE
expression constructs. The SH-SY5Y cell line does not have either APP or ApoE and was
transfected with both. Liposomes containing the desired protein were made using lipofectamine
to introduce the proteins to the cells.
Cellular Fractionation:
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In order to perform cellular fractionation, a kit from Thermo scientific was used. After
harvesting the cells into the appropriate centrifuge tubes, one being a control of A172 cells that
have not had ApoE4 transfected and one that has had APOE4 transfected. The appropriate
reagents were added and spun down in the centrifuge at the appropriate speeds. After each spin
the supernatant was removed and kept in the appropriate tube that pertains to that fraction. After
the fractionation there was two fractions: the cytoplasmic extract and the nuclear extract. When
doing this with the SH-SY5Y cells there was a control, SH-SY5y cells transfected with ApoE,
and SH-SY5Y cells transfected with APP. After doing the fractionation for each different cell
line, a western blot was ran and the membranes were probed for ApoE and APP to see in which
fractionation these are both found. This method was used to show where in the cell ApoE4 is
localized.
Co-Immunoprecipitation:
In order to look at the interaction between sirtuins and ApoE4 co-immunoprecipitation
was used. This is the precipitation of a protein antigen using an antibody. Using the A172 cells
and the SH-SY5Y cells, immunoprecipitation involves using beads that contain the primary
antibody we are looking for. These beads allow for a high binding capacity. The wash steps and
centrifugation allowed for the lysates to be separated, yielding our target protein more
specifically. The precipitated protein was then examined using western blotting and examined
what other protein interacts with it. This method gave us the data to see whether these two
proteins do interact with each other
Western Blotting:
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Using SDS-page, the presence of ApoE, APP, and Sirtuins was determined in A172 and SHSY5y cell lines. Western blotting was used after cell fractionation to show what part of the cell
these proteins are localized in and also after Co-Ip in order to see the interaction between ApoE
and sirtuins. The blots were probed with antibodies that are epitope-specific for ApoE, APP, and
SirT1 and 2.
AlphaLISA:
This technique allowed for the use of cell cultures to measure sAPPα levels and Aβ levels before
and after drug testing. sAPPα and Aβ were standardized to produce a ratio between the two.
SirT1 Assay:
This kit was used on cells that were treated with a variety of different drugs. By adding a
substrate and developer, a plate reader gave the calculations of the amount of SirT1 in each well.
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Tables:
Library Names

Drug Names

13B5

Riboflavin

5B6

Clonidine

10H7

Alaproclate

5C2

Kinase Inhibitor

6B2

Kinase Inhibitor

4C4

Clonidine
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